Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

COVID-19-associated ARDS treated with DEXamethasone (CoDEX): Study design and rationale for a randomized trial

Bruno M. Tomazini, Israel S. Maia, Flavia R. Bueno, Maria Vitoria A.O. Silva, Franca Pellison Baldassare, Eduardo Leite V. Costa, Ricardo A.B. Moura, Michele Honorato, André N. Costa, Alexandre B. Cavalcanti, Regis Rosa, Álvaro Avezum, Viviane C. Veiga, Renato D. Lopes, Lucas P. Damiani, Flávia R. Machado, Otavio Berwanger, Luciano C.P. Azevedo, for the COALITION COVID-19 Brazil III Investigators
doi: https://doi.org/10.1101/2020.06.24.20139303
Bruno M. Tomazini
1Hospital Sírio-Libanês, São Paulo, Brazil
2University of São Paulo, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Israel S. Maia
3HCor Research Institute, São Paulo, Brazil
4Brazilian Research in Intensive Care Network (BRICNet), São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Flavia R. Bueno
1Hospital Sírio-Libanês, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Vitoria A.O. Silva
1Hospital Sírio-Libanês, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Franca Pellison Baldassare
1Hospital Sírio-Libanês, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eduardo Leite V. Costa
1Hospital Sírio-Libanês, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ricardo A.B. Moura
1Hospital Sírio-Libanês, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele Honorato
1Hospital Sírio-Libanês, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
André N. Costa
1Hospital Sírio-Libanês, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandre B. Cavalcanti
3HCor Research Institute, São Paulo, Brazil
4Brazilian Research in Intensive Care Network (BRICNet), São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Regis Rosa
4Brazilian Research in Intensive Care Network (BRICNet), São Paulo, Brazil
5Hospital Moinhos de Vento, Porto Alegre, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Álvaro Avezum
6Hospital Alemão Oswaldo Cruz, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viviane C. Veiga
7BP – A Beneficência Portuguesa de São Paulo, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renato D. Lopes
8Brazilian Clinical Research Institute (BCRI), São Paulo, Brazil
9Duke University Medical Center, Duke Clinical Research Institute, Durham, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucas P. Damiani
3HCor Research Institute, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Flávia R. Machado
4Brazilian Research in Intensive Care Network (BRICNet), São Paulo, Brazil
10Federal University of São Paulo, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Otavio Berwanger
11Hospital Israelita Albert Einstein, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luciano C.P. Azevedo
1Hospital Sírio-Libanês, São Paulo, Brazil
2University of São Paulo, São Paulo, Brazil
4Brazilian Research in Intensive Care Network (BRICNet), São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: luciano.azevedo@hsl.org.br
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

OBJECTIVES The infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) spreads worldwide and is considered a pandemic. The most common manifestation of SARS-CoV2 infection (Coronavirus disease 2019 - COVID-19) is viral pneumonia with varying degrees of respiratory compromise and up to 40% of hospitalized patients might develop Acute Respiratory Distress Syndrome (ARDS). Several clinical trials evaluated the role of corticosteroids in non-COVID-19 ARDS with conflicting results. We designed a trial to evaluate the effectiveness of early intravenous dexamethasone administration on the number of days alive and free of mechanical ventilation within 28 days after randomization in adult patients with moderate or severe ARDS due to confirmed or probable COVID-19.

METHODS This is a pragmatic, prospective, randomized, stratified, multicenter, open-label, controlled trial including 350 patients with early-onset (less than 48h before randomization) moderate or severe ARDS, defined by the Berlin criteria, due to COVID-19. Eligible patients will be randomly allocated to either standard treatment plus dexamethasone (intervention group) or standard treatment without dexamethasone (control group). Patients in the intervention group will receive dexamethasone 20mg IV once daily for 5 days, followed by dexamethasone 10mg IV once daily for additional 5 days or until Intensive Care Unit (ICU) discharge, whichever occurs first. The primary outcome is ventilator-free days within 28 days after randomization, defined as days alive and free from invasive mechanical ventilation. Secondary outcomes are all-cause mortality rates at day 28, evaluation of the clinical status at day 15 assessed with a 6-level ordinal scale, mechanical ventilation duration from randomization to day 28, Sequential Organ Failure Assessment (SOFA) Score evaluation at 48h, 72h and 7 days and ICU-free days within 28.

ETHICS AND DISSEMINATION This trial was approved by the Brazilian National Committee of Ethics in Research (Comissão Nacional de Ética em Pesquisa - CONEP) and National Health Surveillance Agency (ANVISA). An independent data monitoring committee will perform interim analyses and evaluate adverse events throughout the trial. Results will be submitted for publication after enrolment and follow-up are complete.

ClinicalTrials.gov identifier NCT04327401

Competing Interest Statement

This study is supported by Hospital Sirio-Libanes and by Aché pharmaceutical who provided the study drug, the drug logistics distribution to the study centers and insurance for the patients. Dr Berwanger reported research grants from AstraZeneca, Bayer, Amgen, Boehringer-Ingelheim, BMS, Servier, and Novartis. Dr. Lopes reported grants and personal fees from Bristol-Myers Squibb and Pfizer, personal fees from Boehringer Ingelheim and Bayer AG and grants from Amgen Inc, GlaxoSmithKline, Medtronic PLC, and Sanofi Aventis outside the submitted work. Dr. Avezum reported research grants from Bayer, Sanofi-Pasteur, Population Health Research Institute. Dr. Azevedo reported consulting fees from Halex-Istar and Baxter. Dr. Flavia Bueno reported consulting fees from Endpoint Health. All other authors report no conflicts of interest.

Clinical Trial

NCT04327401

Funding Statement

This research is funded by Hospital Sirio-Libanes. The Aché pharmaceutical provided the study drug, the drug logistics distribution to the study centers and insurance for the study patients' but will have no participation or interfere with the trial design, enrolment, analysis, manuscript writing, or publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This trial was approved by the Brazilian National Committee of Ethics in Research (Comissão Nacional de Ética em Pesquisa - CONEP) and National Health Surveillance Agency (ANVISA)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Institution: Hospital Sírio-Libanês

  • Founding source: This research is funded by Hospital Sirio-Libanes. The Aché pharmaceutical provided the study drug, the drug logistics distribution to the study centers and insurance for the study patients’ but will have no participation or interfere with the trial design, enrolment, analysis, manuscript writing, or publication.

Data Availability

This is a protocol for an ongoing randomized controlled trial. We plan to upload the study dataset to a public database 3 months after database lock.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted June 26, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
COVID-19-associated ARDS treated with DEXamethasone (CoDEX): Study design and rationale for a randomized trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
COVID-19-associated ARDS treated with DEXamethasone (CoDEX): Study design and rationale for a randomized trial
Bruno M. Tomazini, Israel S. Maia, Flavia R. Bueno, Maria Vitoria A.O. Silva, Franca Pellison Baldassare, Eduardo Leite V. Costa, Ricardo A.B. Moura, Michele Honorato, André N. Costa, Alexandre B. Cavalcanti, Regis Rosa, Álvaro Avezum, Viviane C. Veiga, Renato D. Lopes, Lucas P. Damiani, Flávia R. Machado, Otavio Berwanger, Luciano C.P. Azevedo, for the COALITION COVID-19 Brazil III Investigators
medRxiv 2020.06.24.20139303; doi: https://doi.org/10.1101/2020.06.24.20139303
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
COVID-19-associated ARDS treated with DEXamethasone (CoDEX): Study design and rationale for a randomized trial
Bruno M. Tomazini, Israel S. Maia, Flavia R. Bueno, Maria Vitoria A.O. Silva, Franca Pellison Baldassare, Eduardo Leite V. Costa, Ricardo A.B. Moura, Michele Honorato, André N. Costa, Alexandre B. Cavalcanti, Regis Rosa, Álvaro Avezum, Viviane C. Veiga, Renato D. Lopes, Lucas P. Damiani, Flávia R. Machado, Otavio Berwanger, Luciano C.P. Azevedo, for the COALITION COVID-19 Brazil III Investigators
medRxiv 2020.06.24.20139303; doi: https://doi.org/10.1101/2020.06.24.20139303

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Intensive Care and Critical Care Medicine
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (941)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (418)
  • Epidemiology (8967)
  • Forensic Medicine (4)
  • Gastroenterology (417)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1320)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (211)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10764)
  • Intensive Care and Critical Care Medicine (570)
  • Medical Education (199)
  • Medical Ethics (52)
  • Nephrology (221)
  • Neurology (1815)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1891)
  • Public and Global Health (4107)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (361)
  • Respiratory Medicine (547)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (206)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)